ALT

Stats

Summary

altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current

Market Cap: 612 Million

Primary Exchange: NASDAQ

Website: https://altimmune.com/

Shares Outstanding: 53.7 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.2462702082236652

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 2087 trading days

From: 2017-01-10 To: 2024-03-07

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated
2017-01-23		2017-01-24	2016-11-17	2.9100000858306885	Cash

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor
2017-05-05				10.0	1.0	10.0